Study of 75 Gliomas Links 54% of Recurrences to Genetic Shifts and Immune-Driven Resistance
Updated
Updated · Nature.com · Jun 3
Study of 75 Gliomas Links 54% of Recurrences to Genetic Shifts and Immune-Driven Resistance
2 articles · Updated · Nature.com · Jun 3
Summary
Researchers profiled 75 longitudinal IDH-mutant glioma samples from 35 patients and found recurrent tumors often shift toward less differentiated, more proliferative cell states tied to treatment resistance.
Fifty-four percent of patients acquired at least one recurrence-associated genetic change—including hypermutation, higher copy-number burden, small deletions or cell-cycle alterations—and those changes were enriched in tumors with worsening grade.
A separate mesenchymal-like state rose at recurrence even without new genetic alterations, instead tracking with higher macrophage abundance; radiotherapy was linked to a microglia-to-macrophage shift in the tumor microenvironment.
Single-nucleus RNA and chromatin data showed these malignant states are epigenetically encoded, while experiments suggested PDGFRA amplification and CDKN2A loss can push tumors toward stem-like states and PDGFRA inhibition can reverse part of that shift.
Higher mesenchymal-like fractions in recurrent astrocytoma and oligodendroglioma were associated with worse overall survival, pointing to both tumor genetics and immune context as targets for future therapy.
How can we defeat brain tumors that use two different escape routes—genetics and environment—to survive therapy?
If standard radiotherapy can make brain tumors more aggressive, is it time to rethink this cornerstone of cancer treatment?
Recurrent Glioma in 2025-2026: Genetic Shifts, Immune Barriers, and the Rise of Personalized Treatment Strategies
Overview
Glioma recurrence poses a major challenge in oncology due to the tumor’s remarkable ability to adapt and resist therapies. This process is driven by a complex interplay of genetic shifts within cancer cells and evolving resistance mechanisms, including those influenced by the immune system. Recent studies using advanced sequencing technologies have shown that recurrent gliomas are not just regrowths but become fundamentally altered and more aggressive. Tumor cells transform their identities over time, behaving like shape-shifters to survive treatment pressures. Understanding these dynamic changes is crucial for developing more effective, adaptive therapies against recurrent glioma.